Case Report

Terminal Complement Pathway Deficiency in an Adult Patient with Meningococcal Sepsis

F. Staels,1,2 W. Meersseman,3,4 P. Stordeur,5 K. Willekens,6 S. Van Loo,6 A. Corveleyn,6 I. Meyts,7,8 G. Meyfroidt,9,10 and R. Schrijvers2,3

1Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
2Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium
3Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium
4Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Infectious and Inflammatory Disease, KU Leuven, Leuven, Belgium
5Belgian National Reference Center for the Complement System, Laboratory of Immunology, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium
6Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
7Department of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium
8Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
9Department of Cellular and Molecular Medicine, Laboratory of Intensive Care, KU Leuven, Leuven, Belgium
10Department of Intensive Care, University Hospitals Leuven, Leuven, Belgium

Correspondence should be addressed to F. Staels; frederik.staels@kuleuven.be and R. Schrijvers; rik.schrijvers@uzleuven.be

Received 16 September 2021; Accepted 26 April 2022; Published 23 May 2022

Academic Editor: Ahmad Mansour

The complement system is an essential part of our innate immune system. Three enzymatic activation pathways are described, all converging into a common terminal pathway which causes lysis of the target cell. Late complement deficiencies (LCDs) are typically diagnosed in children or adolescents with invasive meningococcal disease (IMD). However, IMD can also be a first manifestation in adulthood and should prompt for the evaluation of the LCD. We report the case of a young adult with IMD who was found to have a LCD, caused by a compound heterozygous mutation in C6. His vaccination status was optimized and prophylactic antibiotic treatment was initiated. By means of this case, we would like to raise awareness of underlying LCD in (young) adults presenting with IMD by N. meningitidis. Screening for complement deficiencies after IMD, followed by genetic testing, can be lifesaving and allows for genetic counselling. In addition, we discuss the diagnosis and treatment of LCD.

1. Introduction

The complement system is part of our innate immunity, functioning as a first line of defense against bacterial infections. It is organized in three pathways: the classical pathway (CP), alternative pathway (AP), and lectin pathway (LP) [1, 2]. These pathways, initiated through different mechanisms, converge to a common terminal pathway (Figure 1(a)). In the terminal pathway, C5 convertase cleaves C5 to C5b which recruits C6, C7, C8, and C9 to form the membrane-attack-complex (MAC) [1, 2]. This complex forms a pore in the membrane, leading to lysis of the pathogen. Complement deficiencies in the early pathway are associated with diverse autoimmune diseases such as systemic lupus erythematosus (SLE) [3] with or without infectious susceptibility (mostly by encapsulated bacteria). In contrast, deficiencies in the terminal pathway (LCD) are typically seen in a pediatric population presenting with...
invasive meningococcal disease caused by *Neisseria meningitidis* (IMD) [4, 5]. However, IMD can also manifest in adulthood unmasking an underlying LCD [6]. We report the case of an 18-year-old man who presented with IMD and was confirmed to have a LCD due to a compound heterozygous mutation in C6 resulting in absent C6 levels.

2. Case Presentation

An 18-year-old Surinam patient (Figure 2(a)), born to non-consanguineous parents, presented with high grade fever (39.9°C), vomiting, diffuse myalgia, headache, and petechial bleeding on the arms and trunk. Clinical evaluation showed
signs of meningeal irritation and skin petechiae. Laboratory analysis showed elevated inflammatory parameters (CRP 360 mg/L, reference <5 mg/L; neutrophils 11.3 × 10^3/μL, reference 1.5–5.7 × 10^3/μL). Blood cultures were negative, and the patient received empirical treatment with ceftriaxone (2 g BID). Lumbar puncture was not performed due to anticoagulation for an unprovoked pulmonary embolism 5 months earlier. The patient rapidly improved under antibiotic treatment, suggesting an infectious cause of meningitis.

Nine months later, he was readmitted to the intensive care unit with diffuse myalgia, fever (39.6°C), abdominal pain, headache, and somnolence. Blood analysis showed elevated inflammatory parameters (CRP 164 mg/L, neutrophils 6.2 × 10^3/μL), thrombopenia (90 × 10^3/μL, reference platelets 150–400 × 10^3/μL), impaired renal function (creatinine 1.81, reference 0.72–1.21 mg/dL), and a metabolic acidosis (arterial pH 7.31; lactate 99.1 mg/dL, reference 5.5–14.4 mg/dL; bicarbonate 13.4 mmol/L, reference 21–28 mmol/L; pCO2 27.4 mmHg, reference 35–48 mmHg). Blood cultures were positive for N. meningitidis. Transthoracic echocardiography showed a decreased left ventricular ejection fraction (25%, reference 55–70%). Fluid resuscitation and vaso-andinopressors were initiated for a combined septic and cardiogenic shock. Because of progressive hypoxic respiratory failure, mechanical ventilation was initiated. Antibiotics (ceftriaxone 2 g BID and amikacin 1 g once) were initiated. However, despite early treatment initiation, he progressively developed purpura fulminans (Figure 2(b)) with diffuse intravascular coagulation and rhabdomyolysis.

Figure 2: (a) Family pedigree and genotype. Compound heterozygosity was found in the index patient for c.1879delG, p.Asp627Thrfs*4 (classified as known pathogenic) and c.1591C > T, p.Arg531* (predicted as a complete loss of function, unreported) and homozygosity was found in the siblings for c.1879delG. The mother was carrier for c.1879delG. Genetic material of the father was not accessible (familial reasons) and no further exploration on the inheritance mechanism was performed. (b) Clinical presentation of purpura fulminans at second admission. (c) Top: C6 gene structure, containing 18 exons, and pathogenic intronic mutations (n = 3) affecting the splicing of C6 are shown (orange); bottom: C6 protein structure encoded by the corresponding exons (italic) with known pathogenic missense/nonsense mutations in black (n = 8) and frameshift mutations in blue (n = 4), source: Human Gene Mutation Database. The position of the pathogenic mutations in the index patient is depicted (red, purple).
of his limbs complicated by a compartment syndrome necessitating amputation of his left upper arm and multiple fasciotomies of other limbs. After five months on the intensive care unit, the patient was discharged for intensive rehabilitation. The occurrence of recurrent meningitis, once confirmed due to *N. meningitidis* serogroup Y, raised suspicion of a complement deficiency. Functional testing revealed a decreased classical and alternative pathway activity, with normal C3 and C4 suggesting a LCD (Table 1). Genetic testing revealed the presence of compound heterozygous mutations in C6 (Figure 2(a)). The C6 level was proved to be deficient (Table 1), confirming the pathogenicity of the mutations. The screening of siblings demonstrated that both were affected. The patient and siblings received conjugated meningococcal vaccines for serotypes A/C/W/Y and B, pneumococci, and *H. influenzae* type B. Prophylactic antibiotics (azithromycin 3x/week) were started.

### 3. Discussion

Establishing a diagnosis of an inherited complement deficiency is crucial in patients with IMD. Up to 20% of the patients suffering from IMD lack any of the terminal complement components, or properdin, the latter leading to an X-linked deficiency of the alternative pathway [7]. Meningococcal isolates causing IMD in LCD patients commonly belong to minor or uncommon serogroups, especially serogroup Y, although no specific correlation between LCD and a certain capsular group was found [5, 8]. In this case, a complement deficiency was suspected after the second presentation with IMD with isolation of *Neisseria meningitidis* serogroup Y. Screening for complement deficiencies can be performed by determination of the functional activity of the CP (CH50), the AP (AH50), and the MBL pathway [9]. The gold standard for measuring the CH50 is based on the minimal dilution of serum that causes lysis of 50% of sheep erythrocytes. Nowadays, in most laboratories, CH50 is measured using an automated liposome-based immunoassay [10]. In this assay, sensitized liposomes containing glucose-6-phosphate dehydrogenase (G6PD) are mixed with serum together with a substrate containing G6P, nicotinamide adenine dinucleotide, and anti-DNP antibody. Upon liposome lysis, an enzymatic colorimetric reaction occurs which is proportional to the classical complement activity. For measuring AH50, the gold standard assay is similar to the CH50 gold standard approach, but with the use of rabbit erythrocytes (in contrast to sheep erythrocytes, their surface promotes more AP activation) and dilution of serum in a diluent containing blockers of the CP and MBL pathway. Nowadays, this is replaced by an enzyme-linked immunosorbent assay (ELISA) where a plate coated with zymosan (activator of the AP pathway) is incubated with a serum sample and the terminal complement complex (TCC, soluble C5b-9) is measured using an anti-TCC conjugated antibody [10]. LP is not routinely incorporated in the first screening, but can be tested by incubating serum of the patient on a mannan coated plate. Similar to the AP assay, TCC is measured using ELISA [10]. The interpretation of CH50 and AP50 results is shown in Figure 1(b). If CP components are missing (C1q/r/s, C2 or C4), CH50 will be very low or absent with a normal AP50. If AP components are missing (factor B, D or properdin), AP50 will be very low or absent with a normal CH50. In case both AH50 and CH50 are very low or absent, a C3 defect or LCD (C5–9) should be suspected or in rare cases, factor H or I deficiency. After determination of CH50 and AP50, further quantification of individual complement levels can be performed depending on the results. In our patient, both CH50 and AP50 were very low (CH50) or absent (AH50) with normal C3 levels (Table 1). Further quantitative determination of the late components (C5–9) revealed that C6 levels were undetectable (Table 1). Both whole exome and targeted sequencing of the C6 gene in the index patient revealed a compound heterozygous mutation c.1879delG, p.Asp627Thrfs*4 (classified as known pathogenic) and c.1591C>T, p.Arg531* (predicted as a complete loss of function, unreported). Both his siblings were screened for CH50 and AP50 activity and also found to be defective caused by absent C6 levels, while his mother had normal CH50 and AP50 activity. Surprisingly, his siblings had the c.1879delG, p.Asp627Thrfs*4 in homozygosity. Genetic material of the father was not accessible (for familial reasons) and therefore no further exploration on the inheritance mechanism was performed. Before genetic confirmation, an autosomal dominant inheritance pattern could have been conceived. However, dominant complement disorders have hitherto only been associated with atypical hemolytic uremic syndrome in which the risk for meningococcal infections is deemed low, unless after eculizumab treatment [11]. The abnormal CH50 ruled out the only X-linked recessive complement deficiency (properdin deficiency) in the 2 brothers. Furthermore, no defects in CFP (encoding properdin) were found in whole exome sequencing data from the index patient. C6 deficiency is caused by autosomal recessive loss-of-function mutations in C6, with 16 mutations in 65 cases reported (Figure 2(c)). The treatment of LCD includes optimization of vaccination status (tetravalent meningococcal vaccine A/C/W/Y and the recently available vaccine against serogroup B, *H. influenzae* type B, and pneumococcal vaccines), even in asymptomatic patients. Tetravalent meningococcal vaccine and vaccine against serogroup B are available in Belgium but are not included in the routine vaccination scheme and not reimbursed. Efficacy of meningococcal vaccination was assessed in a cohort of 45 Russian patients with LCD, of whom 31 were vaccinated, with a follow up of 3–8 years [12]. Meningitis episodes decreased significantly in the vaccinated versus non-vaccinated group, but still occurred (6 episodes in 4 patients throughout follow-up). Importantly, half of these new meningitis episodes were caused by serogroup B or non-serogroupable meningococci, suggesting that additional vaccination to serogroup B might improve protection against meningococcal infection. Since vaccination is not providing complete protection, prophylactic antibiotics are routinely given to patients with LCD [13]. Randomized controlled trials studying the effectiveness of prophylactic antibiotics are lacking because of the rarity of LCD. A prospective study in South Africa with 40 C6 deficient patients reported beneficial effects of monthly benzathine penicillin G.
in high-risk patients (≥2 episodes of meningococcal infection) on the occurrence of new meningococcal infections [14]. However, the patients in this study were not vaccinated and the control group was not given a placebo. The role of prophylactic antibiotics in this population, in the context of changing epidemiology and increasing vaccination coverage, has not been properly studied. At this moment, the latest recommendation from the European Society of Immunodeficiency Diseases (ESID) is to offer antibiotic prophylaxis based on risk stratification (e.g., living in endemic areas or having a high-risk profession such as nursery care) [15].

In our case, taking into account that these recommendations are not based on RCTs or recent prospective studies, we discussed the options together with the patient and his affected relatives and decided to give prophylactic antibiotics (azithromycin 3 × 250 mg/week, based on previous studies showing efficacy of azithromycin against Neisseria meningitidis isolates [16], stable serum concentrations, and convenience of the regimen) because of the severity of the infection and the psychological impact.

**Ethical Approval**

This case study was conducted in accordance with the principles of the Helsinki Declaration and approved by the ethics committee of the University of Leuven (s58466).

**Consent**

Written informed consent was obtained from the patient.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

FS (11B5520N) is fellow of the Fonds Wetenschappelijk Onderzoek—Vlaanderen National Fund for Scientific Research (FWO). RS and IM are FWO senior clinical investigator fellows (1805518N and 1805821N, respectively) and received funding from KU Leuven C1 (C12/16/024). RS and IM are members of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (Project ID No. 739543).

### Table 1: Summary of demographic, clinical, and complement levels in the index patient and relatives (ND: not determined).

| Age | Infections | II.1 (index) | II.2 | II.3 |
|-----|------------|-------------|------|------|
|     | Classical complement pathway activity (%), 66–113 | 19 years | 38 years | 18 years | 11 years |
|     | Meningococcal sepsis | <12.5 | 98.1 | <12.5 | <12.5 |
|     | Alternative complement pathway activity (%), 20–60 | 0 | 24 | 0 | 0 |
| C3 (7.9–15.2 mg/dl) | | 18.1 | ND | 10.7 | 14.8 |
| C4 (1.6–3.8 mg/dl) | | 3.8 | ND | 1.3 | 2.2 |
| C5 (1.1–25 mg/dl) | | 34.5 | ND | ND | ND |
| C6 (>4.5 mg/dl) | | <0.5 | ND | <0.5 | <0.5 |
| C7 (>5.5 mg/dl) | | 8.9 | ND | ND | ND |
| C8 (>11.2 mg/dl) | | 19.4 | ND | ND | ND |
| C9 (>12.5 mg/dl) | | 17.5 | ND | ND | ND |

### References

[1] N. S. Merle, S. E. Church, V. Fremeaux-Bacchi, and L. T. Roumenina, "Complement system part 1-molecular mechanisms of activation and regulation," *Frontiers in Immunology*, vol. 6, no. 262, 2015.

[2] M. Noris and G. Remuzzi, "Overview of complement activation and regulation," *Seminars in Nephrology*, vol. 33, no. 6, pp. 479–492, 2013.

[3] L. Truedsson, A. A. Bengtsson, and G. Sturfelt, "Complement deficiencies and systemic lupus erythematosus," *Autoimmunity*, vol. 40, no. 8, pp. 560–566, 2007.

[4] L. A. Lewis and S. Ram, "Meningococcal disease and the complement system," *Virendence*, vol. 5, no. 1, pp. 98–126, 2014.

[5] S. N. Ladhani, H. Campbell, J. Lucidarme et al., "Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017)," *BMC Infectious Diseases*, vol. 19, no. 1, p. 522, 2019.

[6] A. Audemard-Verger, E. Descloux, D. Ponard et al., "Infections revealing complement deficiency in adults: a French nationwide study enrolling 41 patients," *Medicine*, vol. 95, no. 19, Article ID e3548, 2016.

[7] J. Schroeder-Braunstein and M. Kirschfink, "Complement deficiencies and dysregulation: pathophysiological consequences, modern analysis, and clinical management," *Molecular Immunology*, vol. 114, pp. 299–311, 2019.

[8] J. Rosain, E. Hong, C. Fieschi et al., "Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies," *The Journal of Infectious Diseases*, vol. 215, no. 8, pp. 1331–1338, 2017.

[9] L. Wen, J. P. Atkinson, and P. C. Giclas, "Clinical and laboratory evaluation of complement deficiency," *The Journal of Allergy and Clinical Immunology*, vol. 113, no. 4, pp. 585–593, 2004.

[10] T. D. Jaskowski, T. B. Martins, C. M. Litwin, and H. R. Hill, "Comparison of three different methods for measuring classical pathway complement activity," *Clinical and Diagnostic Laboratory Immunology*, vol. 6, no. 1, pp. 137–139, 1999.

[11] L. A. McNamara, N. Topaz, X. Wang, S. Hariri, L. Fox, and J. R. MacNeil, "High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine," *American Journal of Transplantation*, vol. 17, no. 9, pp. 2481–2484, 2017.

[12] A. E. Platonov, I. V. Vershinina, E. J. Kuijper, R. Borrow, and H. Kayhty, "Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine," *Vaccine*, vol. 21, no. 27–30, pp. 4437–4447, 2003.
[13] M. Kuruvilla and M. T. de la Morena, "Antibiotic prophylaxis in primary immune deficiency disorders," *Journal of Allergy and Clinical Immunology: In Practice*, vol. 1, no. 6, pp. 573–582, 2013.

[14] P. C. Potter, C. E. Frasch, W. J. M. van der Sande, R. C. Cooper, Y. Patel, and A. Orren, "Prophylaxis against *Neisseria meningitidis* infections and antibody responses in patients with deficiency of the sixth component of complement," *Journal of Infectious Diseases*, vol. 161, no. 5, pp. 932–937, 1990.

[15] N. Brodszki, A. Frazer-Abel, A. S. Grumach et al., "European society for immunodeficiencies (ESID) and European reference network on rare primary immunodeficiency, autoinflammatory and autoimmune diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management," *Journal of Clinical Immunology*, vol. 40, no. 4, pp. 576–591, 2020.

[16] M. Krone, T. T. Lam, U. Vogel, and H. Claus, "Susceptibility of invasive *Neisseria meningitidis* strains isolated in Germany to azithromycin, an alternative agent for post-exposure prophylaxis," *Journal of Antimicrobial Chemotherapy*, vol. 75, no. 4, pp. 984–987, 2020.